Get started
ABIONYX Pharma SAABIONYX Pharma SAABIONYX Pharma SA

ABIONYX Pharma SA

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

ABNX chart


Full chart

ABNX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪71.37 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.130 EUR
Net income (FY)
‪−4.38 M‬ EUR
Revenue (FY)
‪4.55 M‬ EUR
Shares float
‪33.04 M‬
Beta (1Y)
0.00

Employees


Employees (FY)
51
Change (1Y)
−10 −16.39%
Revenue / Employee (1Y)
‪89.24 K‬ EUR
Net income / Employee (1Y)
‪−85.90 K‬ EUR

About ABIONYX Pharma SA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Cyrille Tupin
Website
abionyx.com
Headquarters
Balma
Founded
2005
ISIN
FR0012616852
FIGI
BBG00896C9L3
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. It specializes in the development of treatment for cardiovascular and metabolic disorders. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Balma, France.

Check out other big names from the same industry as ABNX.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ABNX news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ABNX is 2.315 EUR — it has increased by 12.38% in the past 24 hours. Watch ABIONYX Pharma SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange ABIONYX Pharma SA stocks are traded under the ticker ABNX.
ABNX stock has risen by 20.82% compared to the previous week, the month change is a 67.03% rise, over the last year ABIONYX Pharma SA has showed a 78.90% increase.
We've gathered analysts' opinions on ABIONYX Pharma SA future price: according to them, ABNX price has a max estimate of 11.50 EUR and a min estimate of 10.00 EUR. Watch ABNX chart and read a more detailed ABIONYX Pharma SA stock forecast: see what analysts think of ABIONYX Pharma SA and suggest that you do with its stocks.
ABNX reached its all-time high on Jun 1, 2015 with the price of 14.440 EUR, and its all-time low was 0.200 EUR and was reached on Oct 25, 2019. View more price dynamics on ABNX chart.
See other stocks reaching their highest and lowest prices.
ABNX stock is 18.98% volatile and has beta coefficient of 0.00. Track ABIONYX Pharma SA stock price on the chart and check out the list of the most volatile stocks — is ABIONYX Pharma SA there?
Today ABIONYX Pharma SA has the market capitalization of ‪71.43 M‬, it has increased by 5.43% over the last week.
Yes, you can track ABIONYX Pharma SA financials in yearly and quarterly reports right on TradingView.
ABIONYX Pharma SA is going to release the next earnings report on Sep 25, 2025. Keep track of upcoming events with our Earnings Calendar.
ABNX net income for the last half-year is ‪−2.29 M‬ EUR, while the previous report showed ‪−2.09 M‬ EUR of net income which accounts for −9.82% change. Track more ABIONYX Pharma SA financial stats to get the full picture.
No, ABNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 28, 2025, the company has 51 employees. See our rating of the largest employees — is ABIONYX Pharma SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABIONYX Pharma SA EBITDA is ‪−5.09 M‬ EUR, and current EBITDA margin is −111.93%. See more stats in ABIONYX Pharma SA financial statements.
Like other stocks, ABNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIONYX Pharma SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABIONYX Pharma SA technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABIONYX Pharma SA stock shows the strong buy signal. See more of ABIONYX Pharma SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.